Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8602272 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL11775340 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6130819 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6535779 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL9474303 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3270939 | 0.93 | GBA1 (0.45) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL474124 | 0.93 | GBA1 (0.42) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL28942756 | 0.92 | GBA1 (0.44) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL9568882 | 0.92 | GBA1 (0.43) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL7759537 | 0.89 | GBA1 (0.39) | CYP1A2GBA1CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12377098-B2 | Compositions and methods for the treatment of alopecia | FOLLEA INTERNATIONAL (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025096803-A1 | MINOXIDIL ADJUVANT THERAPIES | CARING BRANDS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025080263-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HAIR RE-PIGMENTATION | GOREN OFER A (CZ) | 2025-04-17 | — | — | WO | disclosed |
| EP-4536354-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-118843453-A | Compositions and methods for treating hair loss | 芙丽亚国际公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4440547-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALOPECIA | Follea International (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024172825-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALOPECIA | FOLLEA INTERNATIONAL (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11628132-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220296486-A1 | Minoxidil Adjuvant Therapies | Jupiter Wellness, Inc. | 2022-09-22 | — | — | US | disclosed |
| US-20210059920-A1 | Minoxidil Adjuvant Therapies | JUPITER WELLNESS INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200214958-A1 | Minoxidil Adjuvant Therapies | JUPITER WELLNESS INC. | 2020-07-09 | — | — | US | disclosed |
| US-20090232808-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | APOLLO LIFE SCIENCES LIMITED (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090098069-A1 | TRANSDERMAL, ALCOHOL-FREE, PHARMACEUTICAL COMPOSITIONS | DRUGTECH CORPORATION (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090075963-A1 | TRANSDERMAL HORMONE SPRAY | DRUGTECH CORPORATION (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009036311-A1 | TRANSDERMAL, ALCOHOL-FREE, PHARMACEUTICAL COMPOSITIONS | DRUGTECH CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036355-A1 | TRANSDERMAL HORMONE SPRAY | DRUGTECH CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | CYP1A2 961/4885GBA1 2181/4885CHRNB2 1586/4885 |
| US-20090098069-A1 | TRANSDERMAL, ALCOHOL-FREE, PHARMACEUTICAL COMPOSITIONS | NOTUM, TSLP, FAR1 | CYP1A2 330/4885GBA1 2434/4885CHRNB2 1149/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | CYP1A2 1625/4885GBA1 3437/4885CHRNB2 2152/4885 |
| US-20090232808-A1 | MOLECULES AND CHIMERIC MOLECULES THEREOF | TNFRSF1A, NGFR, TNFRSF9 | CYP1A2 4282/4885GBA1 3169/4885CHRNB2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.